Recombinant Truncated Nucleocapsid Protein as Antigen in a Novel Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assay for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus Infection
Recombinant Truncated Nucleocapsid Protein as Antigen in a Novel Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assay for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus Infection
复制标题
DOI：
10.1128/cvi.00360-06
复制
发表时间：
2007-01
影响因子：
--
通讯作者：
Fuxun Yu;M. Le;S. Inoue;F. Hasebe;M. Parquet;S. Morikawa;K. Morita
中科院分区：
文献类型：
--
作者：
Fuxun Yu;M. Le;S. Inoue;F. Hasebe;M. Parquet;S. Morikawa;K. Morita
摘要：我们报告了使用重组截短的 SARS-CoV 核衣壳蛋白作为抗原，开发了一种针对严重急性呼吸综合征冠状病毒 (SARS-CoV) 的免疫球蛋白 M (IgM) 抗体捕获酶联免疫吸附测定 (MAC-ELISA)。通过使用健康志愿者和实验室确诊的 SARS 患者的血清进行评估，新开发的 MAC-ELISA 具有 100% 的特异性和敏感性。使用从 SARS 患者采集的系列血清样本，通过 SARS-CoV 感染后的 IgM 抗体检测来确定血清转化时间。血清转化检测的中位时间为发病后8天（范围为5至17天），发病后血清转化率第一周为33%，第二周为97%，第三周为100%。与我们之前报告的IgG检测结果相比，IgM检测的中位血清转换时间提前了3天，并且发病后第二周的IgM血清转换率明显高于IgG检测。我们的结果表明，SARS-CoV 感染后 IgM 反应早于 IgG 出现，与其他病原体的反应一致。我们新开发的 MAC-ELISA 系统为确认 SARS-CoV 感染提供了新的选择。
ABSTRACT We report the development of an immunoglobulin M (IgM) antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) for severe acute respiratory syndrome coronavirus (SARS-CoV) by using recombinant truncated SARS-CoV nucleocapsid protein as the antigen. The newly developed MAC-ELISA had a specificity and sensitivity of 100% as evaluated by using sera from healthy volunteers and patients with laboratory-confirmed SARS. Using serial serum samples collected from SARS patients, the times to seroconversion were determined by IgM antibody detection after SARS-CoV infection. The median time to seroconversion detection was 8 days (range, 5 to 17 days) after disease onset, and the seroconversion rates after the onset of illness were 33% by the first week, 97% by the second week, and 100% by the third week. Compared with the results of our previous report on the detection of IgG, the median seroconversion time by IgM detection was 3 days earlier and the seroconversion rate by the second week after the illness for IgM was significantly higher than by IgG assay. Our results indicating that the IgM response appears earlier than IgG after SARS-CoV infection in consistent with those for other pathogens. Our newly developed MAC-ELISA system offers a new alternative for the confirmation of SARS-CoV infection.